GeneDx Holdings Corp.
NASDAQ:WGSMedical - Healthcare Information Services
+$1.52 today
- Market cap
- $1.56B
- Beta
- 1.97
- P/E (TTM)
- -21.8
- EPS (TTM)
- -$2.65
Volume 1.71M
Average 1.28M
WGS Net Receivables
Amounts owed to the company by customers and others, net of allowances for uncollectible accounts.
GeneDx Holdings Corp.NASDAQ: WGS
Net Receivables · Q2 FY2026 · quarter ended Jun 2026
Net receivables rises 74.1% from a year ago
Net receivables stood at $83.61M at the end of Q2 FY2026, up 74.1% from a year earlier and up 8.7% from the prior quarter. Over 3 fiscal years it compounded at +19.7% a year.
Context
- Net receivables amounted to 17.4% of total assets at the end of Q2 FY2026, up 7.0 pp from a year earlier.
- Net receivables increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether net receivables keeps rising in the next quarterly balance sheet after a +74.1% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Net Receivables history
USD · from the balance sheet
- Latest · FY2025
- 74.37M USD
- Year-over-year change
- +97.6%
- 4-year CAGR
- +29.4%
| Period | Period end | Net Receivables | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 74.37M | +97.6% |
| FY2024 | 2024-12-31 | 37.63M | +14.7% |
| FY2023 | 2023-12-31 | 32.82M | -24.3% |
| FY2022 | 2022-12-31 | 43.34M | +63.2% |
| FY2021 | 2021-12-31 | 26.56M | — |
Net Receivables vs competitors
How WGS compares with its peers on the latest reported figures
- WGS's Jun 2026 net receivables of $83.61M is the 3rd highest of the 9 companies compared; the peer median is $58.58M.
- Its year-over-year change of +74.1% is the 2nd highest of 9, against a peer median of -1.1%.
- Net receivables amounts to 17.4% of total assets for WGS, versus a peer median of 9.0%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Jun 2026 | $175.41M | +14.2% | +10.0% | 13.0% | |
| Mar 2026 | $123.8M | +2.8% | +4.3% | 18.4% | |
WGSGeneDx Holdings Corp. | Jun 2026 | $83.61M | +74.1% | +19.7% | 17.4% |
| Mar 2026 | $75.74M | -5.8% | +6.8% | 6.5% | |
BLLNBillionToOne, Inc. | Jun 2026 | $74.89M | +146.1% | — | 10.3% |
| Mar 2026 | $42.26M | -25.0% | +22.7% | 7.7% | |
| Jun 2026 | $14.93M | -5.0% | +16.3% | 11.3% | |
| Mar 2026 | $13.02M | +18.7% | -0.9% | 4.0% | |
IMDXInsight Molecular Diagnostics Inc. | Mar 2026 | $157K | -95.6% | -17.5% | 0.4% |
| Peer median (excluding WGS) | $58.58M | -1.1% | +6.8% | 9.0% | |
Competitors are the stored peer set for WGS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 400.57M | 137.4M | 99.68M | 85.21M | 105M |
| Short-term Investments | 0 | 0 | 30.47M | 55.97M | 66.29M |
| Net Receivables | 26.56M | 43.34M | 32.82M | 37.63M | 74.37M |
| Inventory | 33.46M | 13.67M | 8.78M | 10.65M | 13.95M |
| Other Current Assets | 3.8M | 6.39M | 1.96M | 1.08M | 1.51M |
| Total Current Assets | 483.54M | 212.62M | 182.34M | 197.97M | 268.29M |
| Property, Plant & Equipment (Net) | 62.72M | 84.29M | 59.38M | 58.51M | 69.11M |
| Goodwill | 0 | 0 | 0 | 0 | 13.52M |
| Intangible Assets | 0 | 186.65M | 172.63M | 158.6M | 168.48M |
| Long-term Investments | 900K | 900K | 0 | 0 | 0 |
| Tax Assets | 0 | 54.32M | 0 | 0 | 46.48M |
| Other Non-current Assets | 6.93M | 6.48M | 4.41M | 4.31M | 3.32M |
| Total Non-current Assets | 70.55M | 332.64M | 236.42M | 221.41M | 301.9M |
| Total Assets | 554.09M | 545.26M | 418.76M | 419.38M | 570.19M |
| Account Payables | 44.69M | 46.02M | 10.24M | 7.95M | 2.46M |
| Short-term Debt | 3.42M | 10.87M | 497K | 0 | 8.95M |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 473K | 40K | 0 | 0 | 0 |
| Other Current Liabilities | 52.7M | 67.08M | 30.88M | 30.42M | 67.86M |
| Total Current Liabilities | 101.28M | 144.3M | 58.82M | 54.82M | 108.91M |
| Long-term Debt | 11M | 6.25M | 52.69M | 51.91M | 86.95M |
| Deferred Tax Liabilities | 0 | 56.98M | 1.56M | 965K | 47.24M |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 35.28M | 24.02M | 14.74M | 5.52M | (37.14M) |
| Total Non-current Liabilities | 64.71M | 147.26M | 131.92M | 119.32M | 153.1M |
| Total Liabilities | 165.99M | 291.56M | 190.74M | 174.13M | 262.01M |
| Common Stock | 24K | 38K | 2K | 2K | 3K |
| Retained Earnings | (575.44M) | (1.12B) | (1.3B) | (1.35B) | (1.37B) |
| Accumulated OCI | 0 | 0 | 425K | 830K | 936K |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 388.1M | 253.71M | 228.02M | 245.25M | 308.18M |
| Total Debt | 32.85M | 77.13M | 119.77M | 116.17M | 151.95M |
| Net Debt | (367.72M) | (60.27M) | 20.09M | 30.96M | 46.95M |
GeneDx Holdings Corp.
NASDAQ:WGS
Intrinsic Alpha fair value
Locked
Current Price
$51.96
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.